Targeting calcium signaling in cancer therapy

详细信息    查看全文

• 作者：Chaochu Cui^a ; ^b ; Robert Merritt^b ; ^c ; Liwu Fu^a ; Zui Pan^b ; ^c ; ^d ; ^{zui.pan@uta.edu}
• 关键词：20-GPPD ; 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol ; CaM ; calmodulin ; CaMKII ; calmodulin-dependent protein kinase II ; CBD ; cannabidiol ; CBG ; cannabigerol ; CPZ ; capsazepine ; CRAC ; Ca2+ release-activated Ca2+ channel ; CTL ; cytotoxic T cells ; CYP3A4 ; cytochrome P450 3A4 ; ER/SR ; endoplasmic/sarcoplasmic reticulum ; HCX ; H+/Ca2+ exchangers ; IP3 ; inositol 1 ; 4 ; 5-trisphosphate ; IP3R (1 ; 2 ; 3) ; IP3 receptor (type 1 ; type 2 ; type 3) ; mAb ; monoclonal antibody ; MCU ; mitochondrial Ca2+ uniporter ; MCUR1 ; MC
• 刊名：Acta Pharmaceutica Sinica B
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：7
• 期：1
• 页码：3-17
• 全文大小：729 K
• 卷排序：7

文摘

The intracellular calcium ions (Ca2+) act as second messenger to regulate gene transcription, cell proliferation, migration and death. Accumulating evidences have demonstrated that intracellular Ca2+ homeostasis is altered in cancer cells and the alteration is involved in tumor initiation, angiogenesis, progression and metastasis. Targeting derailed Ca2+ signaling for cancer therapy has become an emerging research area. This review summarizes some important Ca2+ channels, transporters and Ca2+-ATPases, which have been reported to be altered in human cancer patients. It discusses the current research effort toward evaluation of the blockers, inhibitors or regulators for Ca2+ channels/transporters or Ca2+-ATPase pumps as anti-cancer drugs. This review is also aimed to stimulate interest in, and support for research into the understanding of cellular mechanisms underlying the regulation of Ca2+ signaling in different cancer cells, and to search for novel therapies to cure these malignancies by targeting Ca2+ channels or transporters.